Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020

References

• OECD Health Statistics 2021. https://www.oecd.org/els/health-systems/health-expenditure.htm.
   Google Scholar
• OECD and European Union. Health at a Glance: Europa 2020 State of health in the EU cycle. 2020. https://www.oecd.org/health/health-at-a-glance-europe/.
   Google Scholar
• Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: past trends and future challenges. OECD Health Working Papers, No. 87, OECD Publishing, Paris, 2016. https://doi.org/10.1787/5jm0q1f4cdq7-en.
   Google Scholar
• OECD 2020. Public funding of health care. OECD. https://www.oecd.org/health/Public-funding-of-health-care-Brief-2020.pdf.
   Google Scholar
• WHO guideline on country pharmaceutical pricing policies, second edition. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• https://www.who.int/publications/i/item/9789240011878.
   Google Scholar
• Schwierz C. Cost-Containment Policies in Hospital Expenditure in the European Union. Luxembourg: Publications Office of the European Union, 2016. https://ec.europa.eu/info/sites/default/files/dp037_en.pdf.
   Google Scholar
• Seiter A. A practical approach to pharmaceutical policy. Washington DC, The World Bank. 2010. https://documents1.worldbank.org/curated/en/751541468325451548/pdf/552030PUB0Phar10Box349442B01PUBLIC1.pdf.
   Google Scholar
• Toumi M. Introduction to market access for pharmaceuticals. Boca Raton:CRC Press; 2017.
   Google Scholar
• Danzon PM. Competition and Antitrust Issues in the Pharmaceutical Industry. Pennsylvania:The Wharton School, University of Pennsylvania; 2014.
   Google Scholar
• Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017;29:573–584. https://doi.org/10.2147/CEOR.S140063.
   Google Scholar
• Barros P. Pharmaceutical policies in European countries. In: Doar A, editor. Pharmaceutical Markets and Insurance Worldwide (Advances in Health Economics and Health Services Research), vol. 22. Emerald Group Publishing Limited:Bingley; 2010. p. 3–27.
   Google Scholar
• Klemperer P. Bidding markets. J Compet Law Econ. 2007;3:1–47. https://doi.org/10.1093/joclec/nhl017.
   Web of Science ®Google Scholar
• Runeson G, Skitmore M. Tendering theory revisited. Constr Manag Econ. 1999;17(3):285–296.
   Google Scholar
• Schmidt M. Price determination in public procurement: a game theory approach. Eur Financ Account J. 2015;10(1):49–62.
   Google Scholar
• Boyne GA. Competitive tendering in local government: a review of theory and evidence. Public Administration 1998; 76: 695–712.
   Google Scholar
• Kanavos P, Seeley L, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. LSE Heal 2009:1–40.
   Google Scholar
• Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals. 2010;3:471–481. https://doi.org/10.3390/ph3030471.
   Google Scholar
• Maniadakis N, Holtorf AP, Otávio Corrêa J, Gialama F, Wijaya K. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy. 2018;16:591–607. https://doi.org/10.1007/s40258-018-0405-7.
   PubMed Web of Science ®Google Scholar
• Vogler S, Gombocz M, Zimmermann N. Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. J Pharm Heal Serv Res. 2017;8:147–158. https://doi.org/10.1111/jphs.12180.
   Google Scholar
• Casanova-Juanes J, Mestre-Ferrandiz J, Espín-Balbino J. Competition in the off-patent medicine market in Spain: the national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia. Health Policy (New York). 2018;122:1310–1315. https://doi.org/10.1016/j.healthpol.2018.10.008.
   Web of Science ®Google Scholar
• Petrou P. Long-term effect of tendering on prices of branded pharmaceutical products. Health Policy Technol. 2016;5:40–46.
   Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy (New York). 2011;101:146–152. https://doi.org/10.1016/j.healthpol.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Sandberg DM, Pillay A, Kanavos PG. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med. 2019;220:362–370.
   PubMed Web of Science ®Google Scholar
• Simoens S, Cheung R. Tendering and biosimilars: what role for value added services? J Market Access & Health Policy. 2019. 10.1080/20016689.2019.1705120.
   Google Scholar
• Curto S, Ghislandi S, van de Vooren K, Duranti S, Garattini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy. 2014;116:182–187.
   Web of Science ®Google Scholar
• Dalen DM, Locatelli M, Strøm S. Biosimilar bidding in centralized tenders in Norway. Nordic J Health Econ Early view. 2020. 10.5617/njhe.7394.
   Google Scholar
• Christensen E, Hirsch NC, Andersen JV, Ehlers LH. The analogue substitution model: introducing competition in the absence of generic substitution in Danish hospitals. Health Policy. 2022;126:844–852. https://doi.org/10.1016/j.healthpol.2022.05.018.
   Web of Science ®Google Scholar
• Wadmann S, Kjellberg J. New model for prioritised adoption and use of hospital medicine in Denmark since 2017: challenges and perspectives. Health Policy (New York). 2019;123:606–610. https://doi.org/10.1016/j.healthpol.2019.05.007.
   Web of Science ®Google Scholar
• Oxford Research 2019. Evaluation of the Danish Medicine Council. Report prepared by Oxford Research, on behalf of the Danish Regions, April 2019. (in Danish). https://www.regioner.dk/media/11388/evaluering-af-medicinraad_final_120419.pdf.
   Google Scholar
• Danish Medicines Council. https://medicinraadet.dk/om-os/in-english. Accessed July 7, 2020.
   Google Scholar
• Amgros. Therapeutic areas with analogue competition—Amgros. Available at: https://amgros.dk/en/pharmaceuticals/price-negotiations-and-tendering/therapeutic-areas-with-analogue-competition/. Accessed Nov 14, 2020.
   Google Scholar
• European Medicines Agency. https://www.ema.europa.eu/en.
   Google Scholar
• Danish Health Data Authority (DHDA). Historical medicine prices 2020. Available at: https://www.esundhed.dk/Emner/Laegemidler/Medicinpriser#tabpanelE2CA4BB06DB040D6B40925FF6C57F169. Accessed 09-11-2020.
   Google Scholar
• Keller G, Gaciu N. Statistics for management and economics. Hampshire:Cengage; 2002.
   Google Scholar
• Ehlers LH. Introduction to medical market access in Denmark. Copenhagen:Djøf Publishing; 2019.
   Google Scholar
• Thomas CJ, Wilson BJ. Horizontal product differentiation in Auctions and multilateral negotiations. Economica. 2014;81(324):768–787.
   Web of Science ®Google Scholar
• Management sciences for health. Managing access to medicines and health technologies. Arlington, VA: Management Sciences for Health, 2012. https://www.msh.org/sites/default/files/mds3-jan2014.pdf.
   Google Scholar
• Farquharson E, Torres de Mästle C, Yescombe ER. Managing Procurement. How to Engag with Priv Sect Public-Private Partnerships Emerg Mark 2011. https://doi.org/10.1596/9780821378632_ch09.
   Google Scholar
• Klemperer P. What really matters in auction design. J Econ Perspect. 2002;16(1):169–189.
   Web of Science ®Google Scholar